CorestemChemon said Monday it had received official minutes from a Type C meeting with the U.S. Food and Drug Administration (FDA) regarding Neuronata-R, its stem cell therapy for amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease.
According to the minutes, the FDA agreed with the company's plan to evaluate potential efficacy signals observed in previous trials through a new Phase 3b confirmatory study. The trial will be prospective, randomized, double-blind and placebo-controlled.
This means the U.S. regulatory pathway is taking shape, with the company planning to demonstrate the treatment's efficacy in the Phase 3b trial before submitting a biologics license application (BLA), rather than seeking approval based solely on existing clinical data.
CorestemChemon proposed the change in the total score of the 'ALSFRS-R' (ALS Functional Rating Scale) from baseline to Week 24 as the primary efficacy endpoint. The detailed design is to be discussed through subsequent meetings.
There were no major disagreements regarding the efficacy endpoints, inclusion and exclusion criteria, and other matters proposed by CorestemChemon at the FDA meeting. Based on this, the company plans to prepare a Phase 3b confirmatory trial protocol and conduct a 'Type D Meeting' with the FDA.
A foundation for consultation on the use of biomarkers has also been established.
The FDA expressed no disagreement regarding continuing to explore the relationship between neurofilament light chain (NfL) and clinical outcomes, and stated that further discussions are possible based on the Phase 3b protocol and Statistical Analysis Plan (SAP). Accordingly, CorestemChemon can concretize its NfL analysis plan for the Phase 3b trial and continue consultations with the FDA.
Positive assessments continued in the safety field as well. The FDA positively evaluated the safety profile based on the already completed Phase 2 and Phase 3 trials of Neuronta-A and real-world data (RWD). It also agreed to a plan to combine existing data with Phase 3b safety data for submission in the BLA.
CorestemChemon proposed conducting the Phase 3b confirmatory trial of Neuronta-A in South Korea, similar to the preceding Phase 3 trial. The FDA stated that it is open to accepting clinical trial results conducted in South Korea if they meet International Council for Harmonisation (ICH) guidelines, opening up the possibility of using domestic clinical data as a basis for U.S. approval.
Accordingly, CorestemChemon plans to seek simultaneous approval from regulatory authorities in both South Korea and the United States for the Phase 3b confirmatory trial, just as it did for the preceding Phase 3 trial.
A consensus on the basic direction was also confirmed in the non-clinical and Chemistry, Manufacturing, and Controls (CMC) areas of Neuronta-A. The FDA stated that the non-clinical data are generally reasonable to support a license application.
In the CMC area, it conveyed that there is currently no disagreement regarding the plan to use vascular endothelial growth factor (VEGF) as the primary potency assay.
However, regarding comparative bioequivalence tests for changes in suspension and storage period, and changes in manufacturing site, the company plans to conduct a 'Second Type C Meeting' to supplement the FDA's opinions confirmed during the initial 'Type C Meeting'.
While preparing for subsequent FDA meetings on the Phase 3b design and CMC of Neuronta-A, CorestemChemon plans to discuss its commercialization strategy, including manufacturing and distribution within the United States, at a future official meeting.
Neuronta-A is a therapy made from mesenchymal stem cells extracted from the patient's own bone marrow. It received conditional approval in South Korea in 2014 and has been prescribed in medical settings for over 10 years. Through Phase 3 clinical trials concluded in 2024, improvements in efficacy indicators were confirmed in a patient group where the disease progresses relatively slowly. In May of last year, the company received approval from the Ministry of Food and Drug Safety (MFDS) for a change in product license reflecting Phase 3 clinical trial data.
Yang Gil-an, CEO of CorestemChemon, said, "Receiving the FDA meeting minutes has clarified the direction of the U.S. regulatory pathway through the Phase 3b confirmatory trial," adding, "We will concretize the clinical design in subsequent meetings and prepare additional CMC data without any issues."